CARPRIEVE 20 MG FLAVOURED TABLETS FOR DOGS

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

CARPROFEN

Mevcut itibaren:

Norbrook Laboratories Limited

ATC kodu:

QM01AE91

INN (International Adı):

CARPROFEN

Doz:

20 mg/tablet

Farmasötik formu:

Tablets

Reçete türü:

POM

Terapötik grubu:

Canine

Terapötik alanı:

Carprofen

Terapötik endikasyonlar:

N.S.A.I.D

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2011-03-21

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve 20 mg Flavoured Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
20mg
EXCIPIENTS:
For the full list of excipients see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
Light brown, round, flat, bevel edged tablet.
The tablets can be divided into equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in degenerative joint disease in the dog.
The tablets also can be used in the management of post operative pain.
4.3 CONTRAINDICATIONS
Do not exceed the stated dose.
Do not use in cats.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.
Do not use in puppies less than 4 months.
Do not use in cases of hypersensitivity to active substance or to any of the excipients.
Refer to section 4.7 and 4.8
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
See sections 4.3 and 4.5.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 20/05/2016_
_CRN 7021311_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals:
Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage
and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence i